Articoli con mandati relativi all'accesso pubblico - John MariadasonUlteriori informazioni
Non disponibili pubblicamente: 11
FunRich: An open access standalone functional enrichment and interaction network analysis tool
M Pathan, S Keerthikumar, CS Ang, L Gangoda, CYJ Quek, ...
Proteomics 15 (15), 2597-2601, 2015
Mandati: Australian Research Council, National Health and Medical Research Council …
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction
AJ Wilson, AC Chueh, L Tögel, GA Corner, N Ahmed, S Goel, DS Byun, ...
Cancer research 70 (2), 609-620, 2010
Mandati: US National Institutes of Health
Expression of selenium‐binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer
T Li, W Yang, M Li, DS Byun, C Tong, S Nasser, M Zhuang, D Arango, ...
Molecular nutrition & food research 52 (11), 1289-1299, 2008
Mandati: US National Institutes of Health
BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
MC Andrews, A Behren, F Chionh, J Mariadason, LJ Vella, H Do, ...
Journal of Clinical Oncology 31 (35), e448-e451, 2013
Mandati: National Health and Medical Research Council, Australia, Department of …
Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors
GAP Ganepola, RM Mazziotta, D Weeresinghe, GA Corner, CJ Parish, ...
Clinical & experimental metastasis 27, 1-9, 2010
Mandati: US National Institutes of Health
Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK
DK Lau, IY Luk, LJ Jenkins, A Martin, DS Williams, KL Schoffer, F Chionh, ...
Molecular cancer therapeutics 20 (4), 704-715, 2021
Mandati: National Health and Medical Research Council, Australia
Dual antiangiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study
J Mooi, F Chionh, P Savas, J Da Gama Duarte, G Chong, S Brown, ...
Clinical Cancer Research 27 (8), 2159-2167, 2021
Mandati: National Health and Medical Research Council, Australia
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation
AC Chüeh, G Advani, M Foroutan, J Smith, N Ng, H Nandurkar, DS Lio, ...
Oncogene 40 (17), 3015-3029, 2021
Mandati: National Health and Medical Research Council, Australia
IL-36G promotes cancer-cell intrinsic hallmarks in human gastric cancer cells
N Le, I Luk, D Chisanga, W Shi, L Pang, G Scholz, J Mariadason, M Ernst, ...
Cytokine 155, 155887, 2022
Mandati: National Health and Medical Research Council, Australia
Molecular regulators of lipid metabolism in the intestine–Underestimated therapeutic targets for obesity?
M Dávalos-Salas, JM Mariadason, MJ Watt, MK Montgomery
Biochemical pharmacology 178, 114091, 2020
Mandati: National Health and Medical Research Council, Australia
Articles in PresS. Am J Physiol Gastrointest Liver Physiol (August 11, 2011). doi: 10.1152/ajpgi. 00178.2011
H Augenlicht, E Vincan, JM Mariadason
Mandati: US National Institutes of Health
Disponibili pubblicamente: 93
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer
D Mouradov, C Sloggett, RN Jorissen, CG Love, S Li, AW Burgess, ...
Cancer research 74 (12), 3238-3247, 2014
Mandati: Australian Research Council, National Health and Medical Research Council …
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer
NI Fleming, RN Jorissen, D Mouradov, M Christie, A Sakthianandeswaren, ...
Cancer research 73 (2), 725-735, 2013
Mandati: National Health and Medical Research Council, Australia
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
M Mao, F Tian, JM Mariadason, CC Tsao, R Lemos Jr, F Dayyani, ...
Clinical cancer research 19 (3), 657-667, 2013
Mandati: US National Institutes of Health
Genomic and biological characterization of exon 4 KRAS mutations in human cancer
M Janakiraman, E Vakiani, Z Zeng, CA Pratilas, BS Taylor, D Chitale, ...
Cancer research 70 (14), 5901-5911, 2010
Mandati: US National Institutes of Health
HDAC4 promotes growth of colon cancer cells via repression of p21
AJ Wilson, DS Byun, S Nasser, LB Murray, K Ayyanar, D Arango, ...
Molecular biology of the cell 19 (10), 4062-4075, 2008
Mandati: US National Institutes of Health
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ...
Cell death & disease 10 (5), 342, 2019
Mandati: Australian Research Council, National Health and Medical Research Council …
Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors
R Gollamudi, MH Ghalib, KK Desai, I Chaudhary, B Wong, M Einstein, ...
Investigational new drugs 28, 641-649, 2010
Mandati: US National Institutes of Health
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG …
JK Mooi, P Wirapati, R Asher, CK Lee, P Savas, TJ Price, A Townsend, ...
Annals of Oncology 29 (11), 2240-2246, 2018
Mandati: National Health and Medical Research Council, Australia
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
DL Aisner, TT Nguyen, DD Paskulin, AT Le, J Haney, N Schulte, F Chionh, ...
Molecular Cancer Research 12 (1), 111-118, 2014
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software